BACKGROUND: The prognosis for children with brain stem glioma remains grim. Based on studies suggesting efficacy of vincristine and oral VP-16, The Pediatric Oncology Group (POG, now part of the Children's Oncology Group) conducted a study using these agents in combination with standard external beam radiation for children with newly diagnosed brain stem glioma. METHODS: Children were eligible for the study if they 3-21 years of age, had MRI-evidence of a diffuse intrinsic pontine glioma, and had neurologic deficits of <6 months duration. Patients received local radiotherapy to a dosage of 54 Gy. Chemotherapy consisted of two 28-day cycles of vincristine, 1.5 mg/m(2), days 1, 8, and 15 and oral VP-16, 50 mg/m(2), days 1-21, starting concurrent with radiation, and continuing for ten cycles following radiation. RESULTS: Of the 31 children enrolled, 30 were eligible and evaluable for survival and toxicity. Their median age was 8 years (range 3-14 years). Seven patients (23%) had a partial response following radiation, 18 (60%) had stable disease, 2 (7%) had progressive disease, and response in 3 patients (10%) was not measured. All 30 children have died. Overall survival at 1 year was 27 +/- 7% and at 2 years, 3 +/- 2%. The median survival was 9 months (range 3-36 months). Hematologic toxicity was significant; other toxicities included constipation, mucositis, emesis, and infection. CONCLUSION: The addition of vincristine and oral VP-16 to standard external beam radiation causes moderate toxicity and does not improve survival of children with diffuse intrinsic brain stem glioma. (c) 2007 Wiley-Liss, Inc.
BACKGROUND: The prognosis for children with brain stem glioma remains grim. Based on studies suggesting efficacy of vincristine and oral VP-16, The Pediatric Oncology Group (POG, now part of the Children's Oncology Group) conducted a study using these agents in combination with standard external beam radiation for children with newly diagnosed brain stem glioma. METHODS:Children were eligible for the study if they 3-21 years of age, had MRI-evidence of a diffuse intrinsic pontine glioma, and had neurologic deficits of <6 months duration. Patients received local radiotherapy to a dosage of 54 Gy. Chemotherapy consisted of two 28-day cycles of vincristine, 1.5 mg/m(2), days 1, 8, and 15 and oral VP-16, 50 mg/m(2), days 1-21, starting concurrent with radiation, and continuing for ten cycles following radiation. RESULTS: Of the 31 children enrolled, 30 were eligible and evaluable for survival and toxicity. Their median age was 8 years (range 3-14 years). Seven patients (23%) had a partial response following radiation, 18 (60%) had stable disease, 2 (7%) had progressive disease, and response in 3 patients (10%) was not measured. All 30 children have died. Overall survival at 1 year was 27 +/- 7% and at 2 years, 3 +/- 2%. The median survival was 9 months (range 3-36 months). Hematologic toxicity was significant; other toxicities included constipation, mucositis, emesis, and infection. CONCLUSION: The addition of vincristine and oral VP-16 to standard external beam radiation causes moderate toxicity and does not improve survival of children with diffuse intrinsic brain stem glioma. (c) 2007 Wiley-Liss, Inc.
Authors: Erin E Crotty; Sarah E S Leary; J Russell Geyer; James M Olson; Nathan E Millard; Aimee A Sato; Ralph P Ermoian; Bonnie L Cole; Christina M Lockwood; Vera A Paulson; Samuel R Browd; Richard G Ellenbogen; Jason S Hauptman; Amy Lee; Jeffrey G Ojemann; Nicholas A Vitanza Journal: J Neurooncol Date: 2020-06-16 Impact factor: 4.130
Authors: Susanne Kossatz; Brandon Carney; Melanie Schweitzer; Giuseppe Carlucci; Vesselin Z Miloushev; Uday B Maachani; Prajwal Rajappa; Kayvan R Keshari; David Pisapia; Wolfgang A Weber; Mark M Souweidane; Thomas Reiner Journal: Cancer Res Date: 2017-01-20 Impact factor: 12.701
Authors: Gordon Li; Siddhartha S Mitra; Michelle Monje; Kristy N Henrich; C Dana Bangs; Ryan T Nitta; Albert J Wong Journal: J Neurooncol Date: 2012-03-02 Impact factor: 4.130
Authors: Ute Bartels; Johannes Wolff; Lia Gore; Ira Dunkel; Stephen Gilheeney; Jeffrey Allen; Stewart Goldman; Michal Yalon; Roger J Packer; David N Korones; Amy Smith; Kenneth Cohen; John Kuttesch; Douglas Strother; Sylvain Baruchel; Janet Gammon; Mark Kowalski; Eric Bouffet Journal: Neuro Oncol Date: 2014-05-20 Impact factor: 12.300
Authors: Neal Luther; Zhiping Zhou; Pat Zanzonico; Nai-Kong Cheung; John Humm; Mark A Edgar; Mark M Souweidane Journal: Neuro Oncol Date: 2014-02-12 Impact factor: 12.300
Authors: Kristin A Bradley; Tianni Zhou; Rene Y McNall-Knapp; Regina I Jakacki; Adam S Levy; Gilbert Vezina; Ian F Pollack Journal: Int J Radiat Oncol Biol Phys Date: 2012-10-22 Impact factor: 7.038